* Merck & Co Inc reported quarterly adjusted earnings of $1.57 per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $2.13. The mean expectation of eighteen analysts for the quarter was for earnings of $1.50 per share. Wall Street expected results to range from $1.33 to $1.85 per share.
* Revenue rose 4.4% to $16.66 billion from a year ago; analysts expected $16.46 billion.
* Merck & Co Inc's reported EPS for the quarter was $1.24.
* The company reported quarterly net income of $3.16 billion.
* Merck & Co Inc shares had fallen by 7.7% this quarter and lost 3.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 16.1% in the last three months.
* In the last 30 days, fourteen analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Merck & Co Inc is $136.00 This summary was machine generated from LSEG data November 1 at 03:07 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 1.50 1.57 Beat
Jun. 30 2024 2.15 2.28 Beat
Mar. 31 2024 1.88 2.07 Beat
Dec. 31 2023 -0.11 0.03 Beat